Pharmaceuticals News

MOUNTAIN VIEW, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and...

(PRP's) deep tumor control, fewer metastases, a less fibrotic microenvironment, and chemo re-sensitization...RAS inhibition does not directly address

TEL AVIV, Israel, Oct. 07, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage...

Enrollment completed in Part C of THIO-101 Phase 2 study; 65% of 2026 enrollment target reached in pivotal THIO-104 Phase 3 study CHICAGO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc....

Lead ADC candidate BYON14156 harnesses company’s first-in-class antifolate payload platform to overcome major payload resistance challenge seen in current and next-generation ADCs Advancement of...

Press release announcing the findings of a collaborative study with Caregiver Action Network about the caregiver experience.

Full one-year results from the KYSA-8 registrational trial in stiff person syndrome to be reported, demonstrating sustained clinical benefit and a well-tolerated safety profile with no high-grade CRS...

ATSN-201 demonstrated structural and functional benefit in Parts A and B, including microperimetry improvements exceeding the level the FDA has defined as supportive of potential approval Atsena also...

REDWOOD CITY, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and...

Solengepras 150 mg achieved a statistically significant reduction in daily OFF time, with benefit seen at Week 2Statistically significant improvements in secondary endpoints of ON time without...